Johnson & Johnson announced updated results from the Phase 3 CARTITUDE-4 clinical study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) in patients with relapsed or refractory multiple myeloma. The data, already presented, demonstrate that at least 80 percent of as-treated standard-risk patients remained progression-free and did not require further treatment 2.5 years after a single infusion of CARVYKTI® administered as early as second-line therapy. The company highlighted that stronger immune fitness in earlier lines of treatment may be associated with longer progression-free survival. CARVYKTI® is approved in the U.S. and Europe for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, an immunomodulatory agent, and are refractory to lenalidomide.